|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sella A, Yarom N, Zisman A and Kovel S:
Paclitaxel, estramustine and carboplatin combination chemotherapy
after initial docetaxel-based chemotherapy in castration-resistant
prostate cancer. Oncology. 76:442–446. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berthold DR, Pond GR, Soban F, de Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: Updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cortes JE and Pazdur R: Docetaxel. J Clin
Oncol. 13:2643–2655. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang C: Overcoming docetaxel resistance
in prostate cancer: A perspective review. Ther Adv Med Oncol.
4:329–340. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrylak DP: New paradigms for advanced
prostate cancer. Rev Urol. 9:(Suppl 2). S3–S12. 2007.PubMed/NCBI
|
|
7
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee S, Yoon CY, Byun SS, Lee E and Lee SE:
The role of c-FLIP in cisplatin resistance of human bladder cancer
cells. J Urol. 189:2327–2334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park HS, Hong SK, Oh MM, Yoon CY, Jeong
SJ, Byun SS, Cheon J, Lee SE and du Moon G: Synergistic antitumor
effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human
castration-resistant prostate cancer cells. Anticancer Res.
34:3457–3468. 2014.PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Merajver SD, Frank TS, Xu J, Pham TM,
Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE,
Collins FS, et al: Germline BRCA1 mutations and loss of the
wild-type allele in tumors from families with early onset breast
and ovarian cancer. Clin Cancer Res. 1:539–544. 1995.PubMed/NCBI
|
|
12
|
Gudmundsson J, Johannesdottir G,
Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V and
Barkardottir RB: Different tumor types from BRCA2 carriers show
wild-type chromosome deletions on 13q12-q13. Cancer Res.
55:4830–4832. 1995.PubMed/NCBI
|
|
13
|
O'Neill AJ, Prencipe M, Dowling C, Fan Y,
Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran
C, et al: Characterisation and manipulation of docetaxel resistant
prostate cancer cell lines. Mol Cancer. 10:1262011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rangel C, Niell H, Miller A and Cox C:
Taxol and taxotere in bladder cancer: In vitro activity and urine
stability. Cancer Chemother Pharmacol. 33:460–464. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miki Y, Swensen J, Shattuck-Eidens D,
Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM,
Ding W, et al: A strong candidate for the breast and ovarian cancer
susceptibility gene BRCA1. Science. 266:66–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wooster R, Neuhausen SL, Mangion J, Quirk
Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al:
Localization of a breast cancer susceptibility gene, BRCA2, to
chromosome 13q12-13. Science. 265:2088–2090. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akbari MR, Wallis CJ, Toi A, Trachtenberg
J, Sun P, Narod SA and Nam RK: The impact of a BRCA2 mutation on
mortality from screen-detected prostate cancer. Br J Cancer.
111:1238–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alanee SR, Glogowski EA, Schrader KA,
Eastham JA and Offit K: Clinical features and management of BRCA1
and BRCA2-associated prostate cancer. Front Biosci (Elite Ed).
6:15–30. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Francis JC, McCarthy A, Thomsen MK,
Ashworth A and Swain A: Brca2 and Trp53 deficiency cooperate in the
progression of mouse prostate tumourigenesis. PLoS Genet.
6:e10009952010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moro L, Arbini AA, Yao JL, di Sant'Agnese
PA, Marra E and Greco M: Loss of BRCA2 promotes prostate cancer
cell invasion through up-regulation of matrix metalloproteinase-9.
Cancer Sci. 99:553–563. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Egawa C, Miyoshi Y, Takamura Y, Taguchi T,
Tamaki Y and Noguchi S: Decreased expression of BRCA2 mRNA predicts
favorable response to docetaxel in breast cancer. Int J Cancer.
95:255–259. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mullan PB, Quinn JE, Gilmore PM,
McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P,
Song YH, et al: BRCA1 and GADD45 mediated G2/M cell cycle arrest in
response to antimicrotubule agents. Oncogen. 20:6123–6131. 2001.
View Article : Google Scholar
|
|
24
|
Lai D, Visser-Grieve S and Yang X: Tumour
suppressor genes in chemotherapeutic drug response. Biosci Rep.
32:361–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Husain A, He G, Venkatraman ES and Spriggs
DR: BRCA1 up-regulation is associated with repair-mediated
resistance to cis-diamminedichloroplatinum(II). Cancer Res.
58:1120–1123. 1998.PubMed/NCBI
|
|
26
|
Quinn JE, Kennedy RD, Mullan PB, Gilmore
PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a
differential modulator of chemotherapy-induced apoptosis. Cancer
Res. 63:6221–6228. 2003.PubMed/NCBI
|
|
27
|
Tassone P, Tagliaferri P, Perricelli A,
Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F,
Boland CR and Venuta S: BRCA1 expression modulates chemosensitivity
of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer.
88:1285–1291. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stordal B and Davey R: A systematic review
of genes involved in the inverse resistance relationship between
cisplatin and paclitaxel chemotherapy: Role of BRCA1. Curr Cancer
Drug Targets. 9:354–365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang D, Khan S, Sun Y, Hess K, Shmulevich
I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations
with survival, chemotherapy sensitivity, and gene mutator phenotype
in patients with ovarian cancer. JAMA. 306:1557–1565. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chabalier C, Lamare C, Racca C, Privat M,
Valette A and Larminat F: BRCA1 downregulation leads to premature
inactivation of spindle checkpoint and confers paclitaxel
resistance. Cell Cycle. 5:1001–1007. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Papadaki C, Tsaroucha E, Kaklamanis L,
Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E,
Georgoulias V and Souglakos J: Correlation of BRCA1, TXR1 and TSP1
mRNA expression with treatment outcome to docetaxel-based
first-line chemotherapy in patients with advanced/metastatic
non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thompson ME, Jensen RA, Obermiller PS,
Page DL and Holt JT: Decreased expression of BRCA1 accelerates
growth and is often present during sporadic breast cancer
progression. Nat Genet. 9:444–450. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bièche I, Noguès C and Lidereau R:
Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene.
18:5232–5238. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Collins N, Wooster R and Stratton MR:
Absence of methylation of CpG dinucleotides within the promoter of
the breast cancer susceptibility gene BRCA2 in normal tissues and
in breast and ovarian cancers. Br J Cancer. 76:1150–1156. 1997.
View Article : Google Scholar : PubMed/NCBI
|
